Horizon Therapeutics Public Limited Company [NASDAQ: HZNP] plunged by -$2.04 during the normal trading session on Wednesday and reaching a high of $64.04 during the day while it closed the day at $61.58. The company report on October 12, 2022 that Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
— Presentations will feature analyses from the pivotal Phase 3 study of UPLIZNA, including the relationship between B-cell subsets and NMOSD attacks –.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022, Oct. 26-28. UPLIZNA is the first and only anti-CD19 B-cell-depleting humanized monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) and European Commission (EC) for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD.
Horizon Therapeutics Public Limited Company stock has also loss -8.16% of its value over the past 7 days. However, HZNP stock has declined by -22.49% in the 3 months of the year. Over the past six months meanwhile, it has lost -45.22% and lost -42.85% year-on date.
The market cap for HZNP stock reached $14.82 billion, with 230.02 million shares outstanding and 227.91 million shares in the current float. Compared to the average trading volume of 2.86M shares, HZNP reached a trading volume of 4477416 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Horizon Therapeutics Public Limited Company [HZNP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HZNP shares is $105.82 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HZNP stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
SVB Leerink have made an estimate for Horizon Therapeutics Public Limited Company shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on August 04, 2022. While these analysts kept the previous recommendation, UBS raised their target price to Buy. The new note on the price target was released on June 14, 2022, representing the official price target for Horizon Therapeutics Public Limited Company stock. Previously, the target price had yet another raise to $95, while SVB Leerink analysts kept a Mkt Perform rating on HZNP stock.
The Average True Range (ATR) for Horizon Therapeutics Public Limited Company is set at 2.26, with the Price to Sales ratio for HZNP stock in the period of the last 12 months amounting to 3.89. The Price to Book ratio for the last quarter was 2.86, with the Price to Cash per share for the same quarter was set at 7.87. Price to Free Cash Flow for HZNP in the course of the last twelve months was 11.01 with Quick ratio for the last quarter at 3.80.
HZNP stock trade performance evaluation
Horizon Therapeutics Public Limited Company [HZNP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.16. With this latest performance, HZNP shares dropped by -4.36% in over the last four-week period, additionally sinking by -45.22% over the last 6 months – not to mention a drop of -45.66% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HZNP stock in for the last two-week period is set at 41.99, with the RSI for the last a single of trading hit 38.36, and the three-weeks RSI is set at 42.53 for Horizon Therapeutics Public Limited Company [HZNP]. The present Moving Average for the last 50 days of trading for this stock 63.56, while it was recorded at 64.63 for the last single week of trading, and 86.70 for the last 200 days.
Horizon Therapeutics Public Limited Company [HZNP]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Horizon Therapeutics Public Limited Company [HZNP] shares currently have an operating margin of +21.02 and a Gross Margin at +75.37. Horizon Therapeutics Public Limited Company’s Net Margin is presently recorded at +16.57.
Return on Equity for this stock inclined to 12.29, with Return on Assets sitting at 7.25.
Horizon Therapeutics Public Limited Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.80 and a Current Ratio set at 4.00.
Earnings per share (EPS) analysis for Horizon Therapeutics Public Limited Company [HZNP] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HZNP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Horizon Therapeutics Public Limited Company go to 9.40%.
Horizon Therapeutics Public Limited Company [HZNP]: Insider Ownership positions
There are presently around $12,850 million, or 94.00% of HZNP stock, in the hands of institutional investors. The top three institutional holders of HZNP stocks are: VANGUARD GROUP INC with ownership of 20,922,375, which is approximately 2.919% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 14,598,447 shares of the stock with an approximate value of $898.97 million in HZNP stocks shares; and FMR LLC, currently with $745.96 million in HZNP stock with ownership of nearly -20.029% of the company’s market capitalization.
Positions in Horizon Therapeutics Public Limited Company stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 331 institutional holders increased their position in Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] by around 20,939,157 shares. Additionally, 291 investors decreased positions by around 18,110,079 shares, while 78 investors held positions by with 169,619,950 shares. The mentioned changes placed institutional holdings at 208,669,186 shares, according to the latest SEC report filing. HZNP stock had 84 new institutional investments in for a total of 4,757,168 shares, while 77 institutional investors sold positions of 2,957,637 shares during the same period.